Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

Clinical Trials


Please use the search below. See our frequently asked questions regarding clinical trials. 

Showing 1 - 10 of 176

Fairfax Stem Cell Transplant Program: Autologous Transplantation Recipient and Allogeneic Related Donor Data Collection

As a transplant program we are required to collect data to document the quality of our program, maintain accreditation with national and international societies, and to enhance our understanding of stem cell transplant and the response patients have to transplant. Our transplant center sends transplant related information to US Oncology (network that we are affiliated with), the Inova Fairfax Hospital Stem Cell Transplant team, and the Center for International Blood and Bone Marrow Transplant Research (CIBMTR). For those patients having a matched unrelated donor transplant, information will be sent to the National Marrow Donor Program (NMDP). On occasion we supply statistical information to federal and state agencies and insurance companies without specific reference to individual patients.


The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.


This trial seeks to evaluate the efficacy of Macitentan in patients with pulmonary hypertension after left-ventricular device (LVAD) implantation.

This study is a US-based, prospective, double-blind, multicenter, placebo-controlled, randomized 1:1, pulmonary hypertension in LVAD patients trial.


This study seeks to evaluate the effectiveness of sacubatril-valsartan (aka: Entresto) in patients with advanced heart failure.

This is a US, multicenter, placebo-controlled, HFrEF trial. Testing Entresto in patients with any history of NYHA IV symptoms. 26-week study to assess change in NT-proBNP. Sponsor: NIH HF Network.

Showing 1 - 10 of 176